[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,372,801
  • Shares Outstanding, K 78,492
  • Annual Sales, $ 1,550 K
  • Annual Income, $ -258,760 K
  • EBIT $ -326 M
  • EBITDA $ -328 M
  • 60-Month Beta 0.87
  • Price/Sales 2,119.03
  • Price/Cash Flow N/A
  • Price/Book 4.58

Options Overview Details

View History
  • Implied Volatility 52.35% (-4.59%)
  • Historical Volatility 42.35%
  • IV Percentile 9%
  • IV Rank 11.10%
  • IV High 155.78% on 11/10/25
  • IV Low 39.43% on 05/12/26
  • Expected Move (DTE 10) 0.00 (0.00%)
  • Put/Call Vol Ratio 2.33
  • Today's Volume 180
  • Volume Avg (30-Day) 293
  • Put/Call OI Ratio 1.32
  • Today's Open Interest 10,940
  • Open Int (30-Day) 9,978
  • Expected Range 44.28 to 44.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.03
  • Number of Estimates 4
  • High Estimate $-0.96
  • Low Estimate $-1.06
  • Prior Year $-1.01
  • Growth Rate Est. (year over year) -1.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.37 +32.54%
on 07/22/26
44.52 -0.65%
on 08/11/26
+5.12 (+13.09%)
since 07/10/26
3-Month
28.38 +55.85%
on 06/08/26
44.52 -0.65%
on 08/11/26
+11.95 (+37.02%)
since 05/11/26
52-Week
20.19 +119.07%
on 08/12/25
44.52 -0.65%
on 08/11/26
+24.22 (+121.04%)
since 08/11/25

Most Recent Stories

More News
Celldex: Q2 Earnings Snapshot

Celldex: Q2 Earnings Snapshot

CLDX : 44.04 (+2.49%)
Celldex Reports Second Quarter Financial Results and Provides Corporate Update

Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027 Phase 3 barzolvolimab cold urticaria...

CLDX : 44.04 (+2.49%)
Celldex's Phase Three CSU Data Will Either Justify the Mast Cell Biology Bet or Expose It

Barchart Research What to Expect from CLDX Earnings CLDX Generated August 5, 2026 Current Price $41.06 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 5.59% Celldex's Phase Three CSU Data...

CLDX : 44.04 (+2.49%)
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen Profound systemic mast cell depletion,...

CLDX : 44.04 (+2.49%)
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!

In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.

GWRE : 176.41 (+2.01%)
CLDX : 44.04 (+2.49%)
PGEN : 6.88 (-1.71%)
NVO : 47.33 (-0.84%)
AKAM : 117.68 (+0.03%)
SNEX : 66.09 (+2.12%)
ORCL : 145.65 (-3.57%)
ABBV : 250.31 (+0.94%)
GDXJ : 118.28 (-0.42%)
RSP : 220.84 (+0.28%)
VKTX : 33.81 (-1.83%)
LLY : 1,217.05 (-1.21%)
Celldex Announces Planned Transition of Chief Financial Officer

HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire...

CLDX : 44.04 (+2.49%)
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU Seven months after the completion of dosing (Week 76), up...

CLDX : 44.04 (+2.49%)
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases CDX-622 targets the soluble form of stem cell...

CLDX : 44.04 (+2.49%)
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress 

-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria -- -- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX)...

CLDX : 44.04 (+2.49%)
Celldex: Q1 Earnings Snapshot

Celldex: Q1 Earnings Snapshot

CLDX : 44.04 (+2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

3rd Resistance Point 45.45
2nd Resistance Point 44.33
1st Resistance Point 43.65
Last Price 44.04
1st Support Level 41.85
2nd Support Level 40.73
3rd Support Level 40.05

See More

52-Week High 44.52
Last Price 44.04
Fibonacci 61.8% 35.23
Fibonacci 50% 32.35
Fibonacci 38.2% 29.48
52-Week Low 20.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.